Key Points
July 5 (Reuters) - South Korea's Celltrion Healthcare (091990.KQ) has launched a copycat version to AbbVie Inc's (ABBV.N).
Humira at about a 5% discount, adding to the growing competition for the blockbuster rheumatoid arthritis drug in the U.S...
The biosimilar, Yuflyma, became available for sale in the U.S. on Sunday, the company said a day later...
Yuflyma is listed at $6,576.50 per month compared to the current list price of Humira at $6,922 per carton and is available in two device types auto-injector and pre-filled syringe options...
Until recently, it was the world's biggest-selling non-COVID prescription drug, hitting a record $21.2 billion in sales for 2022...
You might be interested in
Boehringer launches unbranded Humira biosimilar at 81% discount
02, Oct, 23Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar of AbbVie's (ABBV.N) Humira with a list price 81% cheaper than the blockbuster rheumatoid arthritis drug.
Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira
03, Jul, 23Coherus BioSciences said on Monday it has launched a copycat version of AbbVie's Humira in the United States at a discount of more than 85% to the blockbuster arthritis drug.